LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

    Sriphoosanaphan, Supachaya / Pantumongkol, Witthawat / Kulpeng, Wantanee / Charonpongsuntorn, Chanchai / Tanwandee, Tawesak / Sukeepaisarnjaroen, Wattana / Sobhonslidsuk, Abhasnee / Tangkijvanich, Pisit

    PloS one

    2024  Volume 19, Issue 3, Page(s) e0300327

    Abstract: Background: Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B compared to best supportive care ...

    Abstract Background: Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B compared to best supportive care (BSC) among uHCC patients in Thailand.
    Methods: We conducted a cost-utility analysis from a societal perspective. We used a three-state Markov model to estimate relevant costs and health outcomes over the lifetime horizon. Local cost and utility data from Thai patients were applied. All costs were adjusted to 2023 values using the consumer price index. We reported results as incremental cost-effectiveness ratios (ICERs) in United States dollars ($) per quality-adjusted life year (QALY) gained. We discounted future costs and outcomes at 3% per annum. We then performed one-way sensitivity analysis and probabilistic sensitivity analysis to assess parameter uncertainty. The budget impact was conducted to estimate the financial burden from the governmental perspective over a five-year period.
    Results: Compared to BSC, A+B provided a better health benefit with 0.8309 QALY gained at an incremental lifetime cost of $45,357. The ICER was $54,589 per QALY gained. The result was sensitive to the hazard ratios for the overall survival and progression-free survival of A+B. At the current Thai willingness-to-pay (WTP) threshold of $4,678 per QALY gained, the ICER of A+B remained above the threshold. The projected budgetary requirements for implementing A+B in the respective first and fifth years would range from 8.2 to 27.9 million USD.
    Conclusion: Although A+B yielded the highest clinical benefit compared with BSC for the treatment of uHCC patients, A+B is not cost-effective in Thailand at the current price and poses budgetary challenges.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Bevacizumab/therapeutic use ; Cost-Benefit Analysis ; Thailand ; Liver Neoplasms/drug therapy ; Quality-Adjusted Life Years ; Antibodies, Monoclonal, Humanized
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-03-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0300327
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.

    Charonpongsuntorn, Chanchai / Tanasanvimon, Suebpong / Korphaisarn, Krittiya / Payapwattanawong, Songwit / Siripoon, Teerada / Pakvisal, Nussara / Juengsamarn, Jitlada / Phaibulvatanapong, Ekkamol / Chindaprasirt, Jarin / Prasongsook, Naiyarat / Udomdamrongkul, Kittipong / Ngamphaiboon, Nuttapong / Sirachainan, Ekaphop

    JCO global oncology

    2022  Volume 8, Page(s) e2200205

    Abstract: Purpose: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study ... ...

    Abstract Purpose: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of atezolizumab plus bevacizumab.
    Materials and methods: From September 2020 to August 2021, 30 patients with unresectable HCC who met the inclusion criteria of atezolizumab plus bevacizumab as first-line treatment were enrolled. Analysis was assessed for progression-free survival, overall survival, adverse events (AEs), and quality of life (QoL).
    Results: The median progression-free survival and overall survival periods were 6.7 and 10.2 months, respectively. The disease control rate was 63.3%. The frequent AEs were proteinuria, hypertension, and hepatitis. Serious AEs included gastrointestinal bleeding, but none of the patients died from serious AEs. The discontinuation rate was 23.3%, and the median number of treatment cycles was 10.5 cycles. In total, 23.3% of the patients continued treatment after 1 year of therapy. The global health status/QoL and physical function scores showed less deterioration at baseline than at 3 and 6 months (median scores = 76.7, 71.6, and 64.1 in QoL and 84.7, 79.6, and 79.0 in physical function, respectively). The HCC18 symptom score index data showed a slow progression of symptom scores from baseline to 3 and 6 months (12.7, 19.6, and 22.3, respectively).
    Conclusion: This study demonstrates that atezolizumab plus bevacizumab is effective and has a safety profile comparable with that of previous studies as first-line therapy for unresectable HCC in a real-world setting and in Thai populations. Data on PROs also demonstrate benefits in terms of patients' QoL and symptoms.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Quality of Life ; Bevacizumab/adverse effects ; Prospective Studies ; Thailand/epidemiology ; Liver Neoplasms/drug therapy ; Patient Reported Outcome Measures
    Chemical Substances atezolizumab (52CMI0WC3Y) ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2022-12-01
    Publishing country United States
    Document type Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2687-8941
    ISSN (online) 2687-8941
    DOI 10.1200/GO.22.00205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.

    Incharoen, Pimpin / Charonpongsuntorn, Chanchai / Saowapa, Sakditat / Sirachainan, Ekaphop / Dejthevaporn, Thitiya / Kampreasart, Kaettipong / Trachu, Narumol / Muntham, Dittapol / Reungwetwattana, Thanyanan

    Asian Pacific journal of cancer prevention : APJCP

    2019  Volume 20, Issue 12, Page(s) 3581–3589

    Abstract: Objective: BIM is a modulator of apoptosis that is triggered by EGFR-TKIs. This study evaluated the role of BIM deletion and its expression as predictor of EGFR-TKI treatment outcome.: Methods: The medical record of 185 EGFR-positive advanced non- ... ...

    Abstract Objective: BIM is a modulator of apoptosis that is triggered by EGFR-TKIs. This study evaluated the role of BIM deletion and its expression as predictor of EGFR-TKI treatment outcome.
    Methods: The medical record of 185 EGFR-positive advanced non-small cell lung cancer (NSCLC) patients with/ without EGFR-TKI treatment between 9/2012 and 12/2014 were retrospectively reviewed. BIM deletion polymorphism and expression were tested by RT-PCR and immunohistochemistry, respectively. Survival outcomes in EGFR-TKI-treated patients were analyzed according to treatment sequence and EGFR mutation. The correlation between BIM deletion polymorphism, expression, response rate (as a function of EGFR-TKI treatment) and schedule was also explored.
    Result: EGFR-TKIs were administered to 139 (75.1%) of the 185 patients: as the first-line in 52 (37.4%) patients and as later-line treatment in 87 (62.6%) patients. Median overall survival (mOS) was significantly longer in EGFR-TKIs treated patients (28.9 vs. 7.4 months, P<0.001). Among L858R-mutated patients, median progression-free survival (mPFS) was significantly longer in first-line EGFR TKI treatment than a later-line (12.6 vs. 6.3 months, P=0.03). BIM deletion polymorphism and expression was detected in 20.2% and 52.7%, respectively. Patients without BIM deletion polymorphism had a significantly longer mOS when treated with a first-line than with a later-line EGFR-TKI (28.9 vs. 20.7 months, P= 0.04). Patients without BIM expression had a significantly longer mPFS (9.6 vs. 7.3 months, P=0.01) better mOS and response rate (RR).
    Conclusion: BIM deletion polymorphism and expression may predict an EGFR-TKI response in patients with EGFR-positive during therapy.
    MeSH term(s) Aged ; Apoptosis/genetics ; Bcl-2-Like Protein 11/genetics ; Bcl-2-Like Protein 11/metabolism ; Biomarkers, Tumor/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/antagonists & inhibitors ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Polymorphism, Single Nucleotide/genetics ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies
    Chemical Substances BCL2L11 protein, human ; Bcl-2-Like Protein 11 ; Biomarkers, Tumor ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2019-12-01
    Publishing country Thailand
    Document type Journal Article
    ZDB-ID 2218955-5
    ISSN 2476-762X ; 1513-7368
    ISSN (online) 2476-762X
    ISSN 1513-7368
    DOI 10.31557/APJCP.2019.20.12.3581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Stress and associated factors with received and needed support in medical students during COVID-19 pandemic: a multicenter study.

    Puranachaikere, Tidarat / Hataiyusuk, Somboon / Anupansupsai, Rungarun / In-Iw, Supinya / Saisavoey, Nattha / Techapanuwat, Tanawat / Arunrodpanya, Fasinee / Charonpongsuntorn, Chanchai / Wiwattanaworaset, Pakawat / Siripongpan, Areerat / Pruttithavorn, Wisarat / Wonglertwisawakorn, Chayut / Pojanapotha, Pichaya / Rueangrong, Butsayanart / Pattrakornkul, Nalinee / Piyawattanametha, Nontaphon / Piyawattanametha, Siriwan / Ratanapichayachai, Dheeravut

    Korean journal of medical education

    2021  Volume 33, Issue 3, Page(s) 203–213

    Abstract: Purpose: The coronavirus disease 2019 (COVID-19) pandemic is a global health crisis that has impacted daily life due to the policies created to contain the outbreak. Recent studies showed that medical students, a high-stress population, experienced ... ...

    Abstract Purpose: The coronavirus disease 2019 (COVID-19) pandemic is a global health crisis that has impacted daily life due to the policies created to contain the outbreak. Recent studies showed that medical students, a high-stress population, experienced deteriorated mental well-being during the pandemic. The aim of the present study was to assess stress and the need for support among Thai medical students during the COVID-19 pandemic, as a multicenter study.
    Methods: The present study was a cross-sectional questionnaire-based study which collected data from second through sixth year medical students. Data was collected during the pandemic from multiple medical schools spanning all six regions of Thailand. Questionnaires included: demographic data; the Thai version of the Perceived Stress Scale-10 (T-PSS-10) assessing stress level and the sources of stress; and the received supports from medical schools, the satisfaction with the supports, and the further necessary needs.
    Results: There were 1,395 medical students who responded to the questionnaires. Mean T-PSS-10 score was 17.8. Most of the sources of stress were related to the changing of teaching and evaluation system. Students residing in larger medical schools were significantly more satisfied with received support and tended to gain greater support than those in medium and small sized schools. Stress-relieving activities arrangement was considered the most sought after additional support by students.
    Conclusion: Medical student stress levels were higher during the pandemic compared to pre-pandemic levels. Stress relieving activities, availability and access to mental health resources, and other strategies to reduce stress among medical students are urgently needed.
    MeSH term(s) Adult ; COVID-19/epidemiology ; Cross-Sectional Studies ; Female ; Humans ; Male ; Pandemics ; SARS-CoV-2 ; Social Support ; Stress, Psychological/epidemiology ; Students, Medical/psychology ; Surveys and Questionnaires ; Thailand/epidemiology
    Language English
    Publishing date 2021-08-27
    Publishing country Korea (South)
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2846769-3
    ISSN 2005-7288 ; 2005-2367 ; 2005-727X ; 1225-8067
    ISSN (online) 2005-7288 ; 2005-2367
    ISSN 2005-727X ; 1225-8067
    DOI 10.3946/kjme.2021.200
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top